Ensuring children have accelerated access to optimal drug formulations
GAP-f is a collaborative framework set-up to deliver fit-for-purpose solutions to provide better medicines to children in LMICs. It promotes a faster, more efficient, and more focused approach to paediatric formulation development.
The global HIV health community has made substantial progress to accelerate the development and uptake of better paediatric products for children living with HIV. To keep this momentum going, GAP-f has formalizing collaboration across sectors to enable accelerated development and availability of optimized treatment options for paediatric infectious diseases, such as HIV, tuberculosis and viral hepatitis.
The Penta Foundation, as lead of the Clinical Research Working Group, is responsible, together with other paediatric clinical research networks from the group, for establishing when needed dosing, safety, and efficacy across all relevant weight bands for each product in the GAP-f portfolio. The Working Group members combine their strengths and experiences as they lead new studies related to the GAP-f portfolio and provide technical support for studies performed by the pharmaceutical industry. Penta relies on a fully functional network with expertise in multiple-disease areas, which clearly provides an advantage in terms of completion time frame and high standards.
To find out more about GAP-f’s work visit the website.
A full recording of the webinar can be found here.